Literature DB >> 33980595

MafF Is an Antiviral Host Factor That Suppresses Transcription from Hepatitis B Virus Core Promoter.

Marwa K Ibrahim1,2, Tawfeek H Abdelhafez1,2, Junko S Takeuchi1,3,4, Kosho Wakae1, Masaya Sugiyama5, Masataka Tsuge6, Masahiko Ito7, Koichi Watashi1, Mohamed El Kassas8, Takanobu Kato1, Asako Murayama1, Tetsuro Suzuki7, Kazuaki Chayama9, Kunitada Shimotohno10, Masamichi Muramatsu1, Hussein H Aly1, Takaji Wakita1.   

Abstract

Hepatitis B virus (HBV) is a stealth virus that exhibits only minimal induction of the interferon system, which is required for both innate and adaptive immune responses. However, 90% of acutely infected adults can clear the virus, suggesting the presence of additional mechanisms that facilitate viral clearance. Here, we report that Maf bZIP transcription factor F (MafF) promotes host defense against infection with HBV. Using a small interfering RNA (siRNA) library and an HBV/NanoLuc (NL) reporter virus, we screened to identify anti-HBV host factors. Our data showed that silencing of MafF led to a 6-fold increase in luciferase activity after HBV/NL infection. Overexpression of MafF reduced HBV core promoter transcriptional activity, which was relieved upon mutation of the putative MafF binding region. Loss of MafF expression through CRISPR/Cas9 editing (in HepG2-hNTCP-C4 cells) or siRNA silencing (in primary hepatocytes [PXB cells]) induced HBV core RNA and HBV pregenomic RNA (pgRNA) levels, respectively, after HBV infection. MafF physically binds to the HBV core promoter and competitively inhibits HNF-4α binding to an overlapping sequence in the HBV enhancer II sequence (EnhII), as seen by chromatin immunoprecipitation (ChIP) analysis. MafF expression was induced by interleukin-1β (IL-1β) or tumor necrosis factor alpha (TNF-α) treatment in both HepG2 and PXB cells, in an NF-κB-dependent manner. Consistently, MafF expression levels were significantly enhanced and positively correlated with the levels of these cytokines in patients with chronic HBV infection, especially in the immune clearance phase. IMPORTANCE HBV is a leading cause of chronic liver diseases, infecting about 250 million people worldwide. HBV has developed strategies to escape interferon-dependent innate immune responses. Therefore, the identification of other anti-HBV mechanisms is important for understanding HBV pathogenesis and developing anti-HBV strategies. MafF was shown to suppress transcription from the HBV core promoter, leading to significant suppression of the HBV life cycle. Furthermore, MafF expression was induced in chronic HBV patients and in primary human hepatocytes (PXB cells). This induction correlated with the levels of inflammatory cytokines (IL-1β and TNF-α). These data suggest that the induction of MafF contributes to the host's antiviral defense by suppressing transcription from selected viral promoters. Our data shed light on a novel role for MafF as an anti-HBV host restriction factor.

Entities:  

Keywords:  MafF; cytokines; hepatitis B virus; inflammation; restriction factors; transcriptional repression; virus-host interactions

Mesh:

Substances:

Year:  2021        PMID: 33980595      PMCID: PMC8274605          DOI: 10.1128/JVI.00767-21

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  70 in total

1.  JASPAR: an open-access database for eukaryotic transcription factor binding profiles.

Authors:  Albin Sandelin; Wynand Alkema; Pär Engström; Wyeth W Wasserman; Boris Lenhard
Journal:  Nucleic Acids Res       Date:  2004-01-01       Impact factor: 16.971

Review 2.  Small Maf proteins (MafF, MafG, MafK): History, structure and function.

Authors:  Fumiki Katsuoka; Masayuki Yamamoto
Journal:  Gene       Date:  2016-04-05       Impact factor: 3.688

3.  Identification of multiple transcription factors, HLF, FTF, and E4BP4, controlling hepatitis B virus enhancer II.

Authors:  H Ishida; K Ueda; K Ohkawa; Y Kanazawa; A Hosui; F Nakanishi; E Mita; A Kasahara; Y Sasaki; M Hori; N Hayashi
Journal:  J Virol       Date:  2000-02       Impact factor: 5.103

4.  Differential regulation of the pre-C and pregenomic promoters of human hepatitis B virus by members of the nuclear receptor superfamily.

Authors:  X Yu; J E Mertz
Journal:  J Virol       Date:  1997-12       Impact factor: 5.103

5.  Novel robust in vitro hepatitis B virus infection model using fresh human hepatocytes isolated from humanized mice.

Authors:  Yuji Ishida; Chihiro Yamasaki; Ami Yanagi; Yasumi Yoshizane; Kazuyuki Fujikawa; Koichi Watashi; Hiromi Abe; Takaji Wakita; C Nelson Hayes; Kazuaki Chayama; Chise Tateno
Journal:  Am J Pathol       Date:  2015-03-17       Impact factor: 4.307

6.  Small Maf proteins heterodimerize with Fos and may act as competitive repressors of the NF-E2 transcription factor.

Authors:  K Kataoka; K Igarashi; K Itoh; K T Fujiwara; M Noda; M Yamamoto; M Nishizawa
Journal:  Mol Cell Biol       Date:  1995-04       Impact factor: 4.272

7.  A conserved region adjacent to the basic domain is required for recognition of an extended DNA binding site by Maf/Nrl family proteins.

Authors:  T K Kerppola; T Curran
Journal:  Oncogene       Date:  1994-11       Impact factor: 9.867

8.  Hepatitis B Virus e Antigen Activates the Suppressor of Cytokine Signaling 2 to Repress Interferon Action.

Authors:  Yi Yu; Pin Wan; Yanhua Cao; Wei Zhang; Junbo Chen; Li Tan; Yan Wang; Zhichen Sun; Qi Zhang; Yushun Wan; Ying Zhu; Fang Liu; Kailang Wu; Yingle Liu; Jianguo Wu
Journal:  Sci Rep       Date:  2017-05-11       Impact factor: 4.379

9.  SPOC1-mediated antiviral host cell response is antagonized early in human adenovirus type 5 infection.

Authors:  Sabrina Schreiner; Sarah Kinkley; Carolin Bürck; Andreas Mund; Peter Wimmer; Tobias Schubert; Peter Groitl; Hans Will; Thomas Dobner
Journal:  PLoS Pathog       Date:  2013-11-21       Impact factor: 6.823

10.  Pan-viral specificity of IFN-induced genes reveals new roles for cGAS in innate immunity.

Authors:  John W Schoggins; Donna A MacDuff; Naoko Imanaka; Maria D Gainey; Bimmi Shrestha; Jennifer L Eitson; Katrina B Mar; R Blake Richardson; Alexander V Ratushny; Vladimir Litvak; Rea Dabelic; Balaji Manicassamy; John D Aitchison; Alan Aderem; Richard M Elliott; Adolfo García-Sastre; Vincent Racaniello; Eric J Snijder; Wayne M Yokoyama; Michael S Diamond; Herbert W Virgin; Charles M Rice
Journal:  Nature       Date:  2013-11-27       Impact factor: 49.962

View more
  1 in total

1.  The kinesin KIF4 mediates HBV/HDV entry through the regulation of surface NTCP localization and can be targeted by RXR agonists in vitro.

Authors:  Sameh A Gad; Masaya Sugiyama; Masataka Tsuge; Kosho Wakae; Kento Fukano; Mizuki Oshima; Camille Sureau; Noriyuki Watanabe; Takanobu Kato; Asako Murayama; Yingfang Li; Ikuo Shoji; Kunitada Shimotohno; Kazuaki Chayama; Masamichi Muramatsu; Takaji Wakita; Tomoyoshi Nozaki; Hussein H Aly
Journal:  PLoS Pathog       Date:  2022-03-21       Impact factor: 6.823

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.